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We infected squirrel monkeys (Saimiri sciureus) with 
Nipah virus to determine the monkeys’ suitability for use as 
primate models in preclinical testing of preventive and ther-
apeutic treatments. Infection of squirrel monkeys through 
intravenous injection was followed by high death rates as-
sociated with acute neurologic and respiratory illness and 
viral RNA and antigen production.
N
ipah virus (NiV) is a highly pathogenic zoonotic 
paramyxovirus that was ﬁ  rst identiﬁ  ed in Malaysia 
and Singapore in 1999 (1). Since the initial outbreak, NiV 
has been associated with human illness in Bangladesh and 
India (2) and was classiﬁ  ed, together with the closely re-
lated Hendra virus, in the genus Henipavirus. Reported 
human death rates varied from 40%–92% (3), and some 
outbreaks were associated with human-to-human transmis-
sion (4). Most human infections led to encephalitis with 
vasculitis-induced thrombosis in the brain and atypical 
pneumonia in certain patients (5,6). Because of the lack of 
efﬁ  cient treatment or a vaccine for Nipah virus and the high 
pathogenicity of the virus in humans, the manipulation of 
NiV requires BioSafety Level 4 (BSL-4) conditions.
Several species of fruit bats of the genus Pteropus are 
considered natural reservoirs of henipaviruses, although 
the disease does not develop in them (7). Pigs were re-
sponsible for amplifying the NiV infection in Malaysia, 
but their death rate was only 10%–15%. Laboratory infec-
tion of piglets caused development of neurologic signs in 
some animals, and NiV was detected in different tissues 
(8). Hamsters in laboratory studies are highly susceptible 
to NiV, and infection develops in multiple organs, includ-
ing the brain (9). Cats infected with NiV in the laboratory 
reproduce the disease observed in naturally infected cats, 
including a severe respiratory and systemic disease, 6–13 
days after infection (10). However, to our knowledge, a 
primate model necessary for preclinical testing of preven-
tive and therapeutic approaches has not been described. We 
therefore assessed the squirrel monkey (Saimiri sciureus) 
as an experimental model of NiV infection.
The Study
We selected these New World monkeys because of 
their availability, reliability as a primate model with which 
to study infectious diseases (11), and suitability as experi-
mental animals in BSL-4 conditions. Thirteen 4-year-old 
male monkeys (0.8–1.0 kg) were imported from a breeding 
colony in French Guiana and housed in the BSL-4 animal 
care facility in Lyon. Experimental methods were approved 
by the Région Rhône Alpes ethics committee.
Twelve monkeys were infected with NiV isolate UM-
MC1 (1), GenBank accession no. AY029767, either intra-
venously or intranasally; for both modes of infection either 
103 or 107 PFU was used. Animals were observed daily for 
2 months for signs of disease onset; tissues were taken dur-
ing the infection and at necropsy or at the end of experi-
ment (Table 1). Blood samples were collected at different 
time points, serum samples were used for antibody analy-
sis, and peripheral blood cells (PBMC) were used for RNA 
isolation. Different organ samples were taken and frozen 
at –80°C for RNA isolation or ﬁ  xed in 4% formalin for 
histopathologic studies.
RNA was extracted from different organs and analyzed 
by 1-step RT-PCR by using high ﬁ  delity PCR enzyme 
blend (Roche Applied Science, Mannheim, Germany) for 
NiV nucleoprotein expression as described (12). Detec-
tion of NiV-speciﬁ  c antibodies in the serum was performed 
simultaneously for all samples by ELISA and virus neu-
tralization assays as described (13). Immunohistochemical 
analysis was conducted on formalin-ﬁ  xed, parafﬁ  n-embed-
ded tissues as described (6).
Onset of clinical illness was observed between 7 and 
19 days postinfection (dpi), with development in the ani-
mals of anorexia, weight loss, and depression (character-
ized by slumped, collapsed body posture and lack of re-
sponsiveness to the environmental triggers). These clinical 
signs progressed for several hours and were associated with 
hyperthermia and an acute respiratory syndrome character-
ized by dyspnea and hyperventilation. During the course 
of the disease, the animals became more obtunded and 
had uncoordinated motor movements, ending, in some in-
stances, with a loss of consciousness and coma (Table 1). 
Although clinical signs were seen in monkeys infected in-
tranasally and intravenously, the disease lasted longer in 
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infected monkeys (2–3 days). With the latter, death was ob-
served in 3 of 4 animals in which the disease was allowed 
to proceed. Clinical signs of illness for intranasally infected 
monkeys were milder and seen only in 2 of 4 animals be-
fore recovery after 3–7 days of illness. Clinical signs ob-
served in monkeys appear to be similar to those reported 
for human infection, including involvement of neurologic 
and respiratory systems. In addition, the incubation period 
for the acute human infection in Malaysia was estimated 
to be from a few days to 2 weeks, total duration of illness 
ranged 2–34 days, and the rate of subclinical infection was 
≈25% (6,14). It is possible that the inclusion of more ani-
mals in the study would have given higher heterogeneity 
in the course of disease, as seen in humans. Intravenous 
infection was much more efﬁ  cient than the intranasal route 
in monkeys, probably because of a better delivery of the 
virus to different tissues.
NiV-speciﬁ  c RNA was detected in various organs only in 
intravenously infected animals (online Appendix Table, www.
cdc.gov/EID/content/16/3/507-appT.htm), demonstrating a 
differential virus spread, depending on time after infection 
and virus dose. Early detection after infection (3 dpi) was 
possible only in animal D, which was infected with a high 
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Table 1. Clinical course of NiV infection in 12 squirrel monkeys* 
Monkey 
Mode of 
infection
Dose,
PFU/mL
Day of 1st 
symptoms
Duration of 
clinical state
Day of 
euthanasia
Clinical state at 
euthanasia Clinical signs
A† IV 10
3 – – 3 Well None
B IV 10
3 10 3 12† Moribund Uncoordinated motor movements, 
prostration and coma
C IV 10
3 19 3 21‡ Moribund Uncoordinated motor movements, 
prostration, and coma
D† IV 10
7 – – 3 Well None
E IV 10
7 7 2 8† Moribund Uncoordinated motor movements, 
prostration, and coma
F IV 10
7 14 3 52 Recovered/well Anorexia, depression
G† IN 10
3 – – 4 Well None
H IN 10
3 – – 52 Well None
I IN 10
3 8 3 56 Recovered/well Anorexia, seizure
J† IN 10
7 – – 4 Well None
K IN 10
7 17 Septic shock not correlated with 
NiV infection
L IN 10
7 10 7 56 Recovered/well Anorexia, seizure, edema of eyes
*IV, intravenous; IN, intranasal; NiV, Nipah virus. 
†Early systematic euthanasia. 
‡Death caused by Nipah virus infection. 
Figure.  Pathologic signs associated with 
Nipah virus infection in squirrel monkeys. 
A) Focal inﬂ  ammation in the lung (monkey 
B). Hematoxylin and eosin stains; original 
magniﬁ  cation  ×10. B) Viral antigens 
(brown staining) were immunolocalized 
to the alveolar walls (monkey E). C) 
brain neuron (monkey B). D) Tubular and 
extratubular cells in the kidney (monkey E). 
E) Lymphoid cells in the spleen (monkey 
D). B–E, immunoperoxidase stains, original 
magniﬁ  cation ×20. Infection of Squirrel Monkeys with Nipah Virus
dose of NiV. Animal F, which recovered from the disease, 
although positive for NiV (by RT-PCR) in the PBMC sam-
ple 2 dpi, was negative after necropsy on day 52, when virus 
was probably eliminated from the monkey. Detection of viral 
RNA in different tissues (liver, brain, spleen, kidney, lung, 
lymph nodes) early after infection suggests a rapid propaga-
tion of NiV and tropism for various tissues. Viral RNA was 
found in PBMC taken at different time points after infection, 
suggesting the role of these cells in viral propagation in the 
monkey. In contrast to what has been observed in hamsters 
(9), viral RNA was not detected in any urine samples from 
analyzed animals, thus excluding urine as a possible mode of 
virus dissemination in this species.
Monkeys showed mild histologic lesions, including 
the inﬂ  ammation most obvious in the lung parenchyma 
(Figure, panel A). In contrast to human infection, vasculitis 
and brain abnormalities were much less evident. However, 
immunohistochemistry showed viral antigens immunolo-
calized to the brain, lung, spleen, and kidney extravascular 
parenchyma, thus conﬁ  rming viral infection in these organs 
(Figure, panels B–E).
NiV-speciﬁ  c immunoglobulin (Ig) M responses were 
observed starting from 8 dpi for all monkeys except in 
groups H and I (Table 2). This ﬁ  nding suggests that 103 PFU 
of NiV delivered intranasally was probably insufﬁ  cient to 
induce infection in monkeys. Although NiV-speciﬁ  c anti-
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Table 2. Detection of anti–Nipah virus antibodies in 12 squirrel monkeys by ELISA and seroneutralization assay* 
Day postinfection 
Monkey 
Mode of 
infection† Serology‡  2 3 or 4 8 or 9 12 17 30 37 52 or 56
A§ IV 10
3 IgM – Neg
IV 10
3 IgG – Neg
IV 10
3 Neutralization – Neg
B¶ IV10
3 IgM Neg – Neg 0.396
IV10
3 IgG Neg – Neg Neg
IV10
3 Neutralization Neg – Neg Neg
C¶ IV10
3 IgM Neg – 0.664 – –
IV10
3 IgG Neg – Neg – –
IV10
3 Neutralization Neg – Neg – –
D§ IV 10
7 IgM – Neg
IV 10
7 IgG – Neg
IV 10
7 Neutralization – Neg
E¶ IV 10
7 IgM Neg – 1.343
IV 10
7 IgG Neg – 0.562
IV 10
7 Neutralization Neg – 40
FI V 1 0
7 IgM Neg – 1.550 – – 0.374 – 0.175
IV 10
7 IgG Neg – 0.369 – – 2.867 – 3.023
IV 10
7 Neutralization Neg – 80 – – >1,280 – >1,280
G§ IN 10
3 IgM Neg Neg
IN 10
3 IgG Neg Neg
IN 10
3 Neutralization Neg Neg
HI N 1 0
3 IgM – – Neg – – Neg – Neg
IN 10
3 IgG – – Neg – – Neg – Neg
IN 10
3 Neutralization – – Neg – – Neg – Neg
II N 1 0
3 IgM – – Neg – – Neg Neg Neg
IN 10
3 IgG – – Neg – – Neg Neg Neg
IN 10
3 Neutralization – – Neg – – Neg Neg Neg
J§ IN 10
7 IgM – Neg
IN 10
7 IgG – Neg
IN 10
7 Neutralization – Neg
KI N 1 0
7 IgM Neg – – – 0.286
IN 10
7 IgG Neg – – – 1.757
IN 10
7 Neutralization Neg – – – 80
LI N 1 0
7 IgM – – 0.375 0.248 Neg
IN 10
7 IgG – – Neg 2.078 2.308
IN 10
7 Neutralization – – Neg 320 320
*IV, intravenous; Ig, immunoglobulin; neg, negative; IN, intranasal.  
†Mode of infection and delivered viral dose (in PFU). 
‡IgG and IgM antibodies were determined by ELISA and results are presented as absorbance readings. Neutralization titers are expressed as reciprocal 
values of 2-fold serum dilutions required to completely inhibit cytopathic effect of 25 PFU of NiV on Vero cells. 
§Early systemic euthanasia: 3 days postinfection (dpi) (A and D) or 4 dpi (G and J). 
¶Death caused by NiV infection: B, 12 dpi; C, 21 dpi; E, 8 dpi. bodies were detected by ELISA in animals dying from the 
infection, sufﬁ  cient titers of neutralizing antibodies did not 
develop in these monkeys and they were therefore not pro-
tected. These ﬁ  ndings suggest the protective role of high 
neutralization titers in NiV infection. Our results agree with 
other studies of NiV infection that reported most human 
patients with fatal NiV infection had IgG and IgM in their 
serum and cerebrospinal ﬂ  uid (6,15); neutralization titers 
were not analyzed in those studies.
Our results suggest some similarities of NiV patho-
genesis in humans and squirrel monkeys, including de-
velopment of clinical signs, progression of infection, and 
humoral immune response. We conclude that the squirrel 
monkey can be used as an animal model for experimental 
studies of NiV infection, and these results pave the way for 
further study. 
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